Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Valeant to present at the Goldman Sachs Conference. June 20
LAVAL, Quebec, May 31, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Paul Herendeen, executive vice president and chief financial officer, and Linda LaGorga, senior vice president, finance and treasurer, are scheduled to present at the following financial Conferences Goldman Sachs Second Annual Leveraged Finance Conference on Tuesday, June 20, 2017 at 10:40 a.m. PDT (1:40 p.m. EDT) at Terranea, Rancho Palos Verde, Calif. A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: http://ir.valeant.com/events-and-presentations About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant and forward looking statements can be found at www.valeant.com. Contact Information Investors: Elif McDonald elif.mcdonald@valeant.com 514-856-3855 877-281-6642 (toll free) Media: Lainie Keller lainie.keller@valeant.com 908-927-0617 Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/) To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-present-at-financial-industry-conferences-300466400.html SOURCE Valeant Pharmaceuticals International, Inc.
how can they be drilling without Permits ???
Just talked to Valent Investor relations.
Very positive and She said we will talk again after 2nd Qtr results are released. This is very exciting !!! Really cheap down at this pps. IMO.
From Barrons
you searching for? Search . Barrons Stocks to Watch Valeant: Accentuate the Positive? Two analyst reports released last week consider the impact of Valeant's iNova sale. By Ben Levisohn June 12, 2017 3:02 p.m. ET Last Thursday, shares of Valeant Pharmaceuticals International (VRX) jumped 9% after the company announced that it had sold its iNova business for more than $900 million, with the proceeds set aside for paying down its debt. And with that, the analyst opinions started rolling in, with BMO glad to see Valeant "execute" but worried about its leverage and Wells Fargo also worried about Valeant's debt load. We couldn't keep up with them all, so we thought we'd throw up two more today. In a report from June 8, RBC's Douglas Miehm and Joel Hurren, who rate Valeant Market Perform with a $19 target price, contend that not only was iNova sold last week, but "more importantly, VRX has executed on its strategy again." They explain: Progress continues toward $5B in debt repayment by February 2018. Management continues to make progress towards its commitment to $5B of debt repayment by Feb/18. Following the iNova close (excl. Dendreon proceeds), VRX will have paid down ~$4.5B since Q1/16. Including Dendreon, VRX will have paid down ~$5.4B in debt by year-end 2017. We view this positively, particularly given recent investor concerns that management had stalled in many of its divestiture talks. Our year-end leverage is now ~7.25x and ~7.00x in 2017E and 2018E, respectively. In a note released on June 8, CFRA's Jeffrey Loo maintained his Buy rating on Valeant: We keep our 12-month target at $17 on below peers 4.25X our 2017 EPS estimate of $4.00. VRX agrees to sell iNova Pharmaceuticals to a company owned by Pacific Equity Partners and The Carlyle Group, for $930M. The deal, subject to approvals, is expected to close in H2 17. iNova markets prescription and over-the-counter products for weight management, pain management, cardiology, and colds, etc. in over 15 countries. VRX will use the proceeds to pay down debt. Along with its pending sale of Dendreon for $820M, VRX will be able to meet its goal of paying down $5B in debt by Shares of Valeant have gained 2.2% to $12.79 at 2:51 p.m. today.
Short interest in Valeant stock sees a dip.
Between the two reporting dates of short interest numbers( May 15 & May 31), Valeant stock has seen a significant correction losing nearly 15%. During the same period, the short interest in Valeant Pharmaceuticals declined by 6.8%. The number of shorted shares on the latest reporting date decreased to 50.47 million from 54.17 million shares at the end of the preceding fortnight. As a percentage of float, short interest dropped to 14.9%, from 16%. The days to cover came in at three days.
Shares of the pharma company continue to struggle due to its past issues. The heavy debt burden has been an issue for the company for some time now but things are beginning to change. The rumor of sale of assets is the new factor which is driving the stock of late.
my chart says that a "Symmetrical Continuation Triangle " Has formed . This is a bullish signal that the price may rise from the close 13.26 to the range 15.10 to 15.60. The Pattern formed over 17 days which is roughly the period time in which the Target price may be achieved. It hit close to 13.45 on Friday where the sell off took place. Time will tell , it always does !
Resistance is at 13.45 where the Friday selloff took place.
Fast Money
On CNBC's "Fast Money Final Trades" Fast Money Picks For June 12 Steve Grasso wants to buyValeant Pharmaceuticals Intl Inc(NYSE:VRX). He thinks it could jump to $20 or $30. http://news.google.com/news/url?sa=T&ct2=ca&fd=S&url=https://www.benzinga.com/media/cnbc/17/06/9592951/amd-us-steel-valeant-fast-money-picks-for-june-12&cid=0&ei=04k-WfGGN8fU2AbX-IHYAw&usg=AFQjCNHTLFDveeaGsqC6xL35bakwp7avgA
I will buy another 5000 shares on Monday .
Trendliner what say you , time to enter buying more ??
probably a pull back tomorrow.
Looks good on Paper again nothing new, no off take ,no permits !!
Rumor or Reality ? >>>>>
VRX about to receive $1.3 billion in upfront payments in exchange for rights to 25% of royalties earned from the sales of three new drugs that VRX is scheduled to launch in late-2017.
You heard it here first.
That's good for us to buy and avg down ... loving it !!
Heading back up now !!!!
VRX NEWS
EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for Post-operative Ocular Inflammation and Pain in Ocular Surgery Patients
WALTHAM, Mass., May 22, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received its first development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”) under the Company’s License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to the Company’s EyeGate® II Delivery System and EGP-437 combination product (the “Product”) in post-operative ocular inflammation and pain in ocular surgery patients.
In 2015, EyeGate and Valeant entered into an agreement granting Valeant exclusive, worldwide commercial and manufacturing rights to EGP-437 in the field of uveitis, as well as a right of last negotiation to license the Product in other indications. In February 2017, the companies entered into a second agreement for the Product in the treatment of post-operative ocular inflammation and pain in ocular surgery patients. Under this agreement, EyeGate is eligible to receive developmental and sales-based milestones totaling up to approximately $99.0 million, as well as royalties on Valeant’s net sales of the product, which will be a part of its Bausch + Lomb Pharmaceuticals business.
Stephen From, President and Chief Executive Officer of EyeGate Pharmaceuticals commented, “We have made significant progress in the development of EGP-437 for the treatment of post-operative ocular inflammation and pain in ocular surgery patients since initiating our first study in this large indication last year, evidenced by this first milestone payment under the Valeant partnership in ocular surgery. Since entering into our initial agreement, in Uveitis, nearly two years ago, Valeant has proven to be an optimal partner and we look forward to continued collaboration as we further advance EGP-437 in both of the licensed indications.”
About EyeGate:
EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate is developing products using CMHA-S, a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries.
EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. For more information, please visit www.EyeGatePharma.com.
Forward-looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate’s products, including EyeGate’s EGP-437 combination product and those of Jade, a wholly owned subsidiary of EyeGate, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading “Risk Factors” contained in our Annual Report on Form 10-K filed with the SEC on February 23, 2017 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Contact:
Lee Roth / Janhavi Mohite
The Ruth Group for EyeGate Pharmaceuticals
646-536-7012 / 7026
lroth@theruthgroup.com / jmohite@theruthgroup.com
EyeGate Pharma
VRX is doing great today moved up from the 12s to the .13s bought in the 12s and made a nice trade. getting ready to buy again in the 12s !
Time to buy VRX released 19 hours ago !
http://www.investopedia.com/news/time-buy-valeant-pharmaceuticals-vrx/
New & Improved Formula Builds on Trusted 30-Year Heritage of Meeting Consumers' Lens Care Solution Needs
LAVAL, Quebec, May 22, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced the launch of renu® Advanced Formula multi-purpose solution for soft and silicone hydrogel contact lenses. This unique formula combines three disinfectants and two moisture agents to provide excellent lens cleaning and disinfection, in addition to all-day comfort.
"At Valeant, we are keenly focused on continuing to drive innovation and enhance our existing portfolio using the most current scientific and clinical research to better meet the needs of our customers and their patients," said Joseph C. Papa, Chairman and CEO of Valeant. "The Bausch + Lomb Consumer Healthcare business remains a critical driver for our global eye health business, offering a wide range of over-the-counter supplements, eye care, and lens care products."
Bausch + Lomb was the first company to bring an 'all-in-one' multi-purpose disinfection solution to market with the launch of the renu brand in 1987. Today, the brand has grown to more than three million users. The new and improved renu Advanced Formula solution will replace renu sensitive and renu fresh solutions beginning in June in major retailers.
Bausch + Lomb's Consumer Healthcare business is one of the fastest growing consumer healthcare businesses in the U.S.1 and the No. 1 category growth contributor (62%) in the eye care category.2 The product portfolio includes such well-known brands as Biotrue® multi-purpose solution the No. 1 multi-purpose solution brand in households with the highest loyalty metrics3, and PreserVision® AREDS 2 Formula Eye Vitamin and Mineral Supplement (120 ct.), the No. 1 selling SKU in the vitamin category and the largest contributor to vitamin category growth.4
In addition to its product portfolio, Bausch + Lomb's Consumer Healthcare business has a rich R&D pipeline that relies on a research strategy to develop new formulations for new and existing products and line extensions, among others. This includes the company's new redness reliever candidate, brimonidine tartrate ophthalmic solution, 0.025% (Luminesse™5), which is currently under review by the U.S. Food and Drug Administration.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.
Forward-looking Statements
This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates", "if approved", "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
1 Based on retail sales
2 Based on IRI Data: Eye Care Category Includes General Eye Care, Lens Care, Vision Accessories, & Eye Vitamins
3 IRI data. Latest 52 wks. ending 01/01/17
4 IRI data. Latest 52 wks. ending 01/01/17
5 Provisionally approved name.
Contact Information:
Elif McDonald
514-856-3855
877-281-6642 (toll free)
elif.mcdonald@valeant.com
Media:
Lainie Keller
908-927-0617
lainie.keller@valeant.com
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/)
The Dumper may have received a Margin Call on VRX or another stock they were margined on and had a big profit in VRX and needed to raise cash FAST !!!
Thank you...... we have a great future, with 50 new drugs being introduced this year generating $100 million in revenues !!!
Ca Chinga !!!!
EU Medicines Agency recommends Valeant's psoriasis drug
Great news for Valeant Stock:
EU Medicines Agency recommends approval of Valeant Pharmaceuticals Inc psoriasis drug Brodalumab.
Guess this will help Valeant going past $20 today!
From the Stock House Board.
New Presentation on Monday Morning at 9:00 am EDT.>>>>>>>>>>>>
Global Healthcare Conference to be held on Monday, May 22, 2017 at 9:00 a.m. EDT at the Grand Hyatt New York hotel; and
A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: http://ir.valeant.com/events-and-presentations
The traders on CNBC's Fast Money are LONG VRX !!!!!!!
Just listened to the webcast VRX is introducing 50 new products this year that should produce $100 mil in revenue.
Presentations ARE TODAY @ Bank of America Merrill Lynch!!!!!
Buy before these presentations. IMHO !
LAVAL, Quebec, May 10, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the following health care conferences:
•Bank of America Merrill Lynch 2017 Healthcare Conference on Wednesday, May 17, 2017 at 3:00 p.m. PDT (6:00 p.m. EDT) at the Wynn Las Vegas hotel;
•UBS Global Healthcare Conference to be held on Monday, May 22, 2017 at 9:00 a.m. EDT at the Grand Hyatt New York hotel; and
•Jefferies 2017 Global Healthcare Conference to be held on Wednesday, June 7, 2017 at 8:30 a.m. EDT at the Grand Hyatt New York hotel.
A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: http://ir.valeant.com/events-and-presentations
Invest for the long haul at E*TRADE.
I'm Betting on CEO Papa !!!
My wife was a Health and Well fair Consultant to Perrigo where CEO Papa took Perrigo to 100 bucks a share ++ and sold the company for lots of mula. Papa is a seasoned CEO and will do the same for VRX. If VRX was $200 pps I also would be shorting VRX. But , Its Not. This is a turnaround situation and at 14 Bucks it has a lot of upside !!! Papa is going on the road with Presentations in LV etc. I am sure he will address the debt situation and his plans to take care of that matter. Also, remember he is paid some with stock and options if VRX does well he well rake in lots of mula, if not he won't.
I'm Betting on CEO Papa !!!!!
Short positions are VIOLENTLY BULLISH !!! >>>
Buy all you can before Wednesday! Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the following health care conferences: Bank of America Merrill Lynch 2017 Healthcare Conference on Wednesday, May 17, 2017 at 3:00 p.m. PDT (6:00 p.m. EDT) at the Wynn Las Vegas hotel.
A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: http://ir.valeant.com/events-and-presentations
IMHO
Buy before these presentations. IMHO !
LAVAL, Quebec, May 10, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the following health care conferences:
•Bank of America Merrill Lynch 2017 Healthcare Conference on Wednesday, May 17, 2017 at 3:00 p.m. PDT (6:00 p.m. EDT) at the Wynn Las Vegas hotel;
•UBS Global Healthcare Conference to be held on Monday, May 22, 2017 at 9:00 a.m. EDT at the Grand Hyatt New York hotel; and
•Jefferies 2017 Global Healthcare Conference to be held on Wednesday, June 7, 2017 at 8:30 a.m. EDT at the Grand Hyatt New York hotel.
A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: http://ir.valeant.com/events-and-presentations
I'm raising my target price from 80$ to 100$
The fundamental of this comany is a classic recovery story.. just look at all the institutional money flocking back in to Valeant Pharma.
This company is a GEM
From the Stockhouse Board
Cramer doesn't know what's going on with VRX !! He said it has a big short and he doesn't see any new drugs coming to market ... He should retire !! VRX has turned over the whole float this week .
Nice Close !!!
$19.40 TSX last trade pps.
Comparison products info. From Stock house board.
Novartis Cosentyx generated sales of over $1 billion in 2016
Valeant's NEW psoriasis drug brodalumab, now branded as Siliq will generate anywhere from $250 million to $1 billion annually in the beginning...
Currently.. Valeant's Psoriasis drug is the cheapest out of all their competitors.
Novartis Cosentyx close to $46,000 for the first year treatment
Johnson & Johnson around $46,000 a year
Eli Lilly Talz over $50,000 for 1 year
Valeant's brodalumab (Siliq) .. only $42,000 a year ( THE LOWEST & THE CHEAPEST )
Let's look at Novartis Consentyx .. they start selling their drug in late 2015 and generated $261 million..... and in 2016 /// full year annual sales of Consentyx equals $1.1 BILLION.
Valeant sales in brodalumab (Siliq) will probably generate $350 million in the 2nd half of 2017... once more and more doctors and patients recognized the brand.... sales will really pick up in 2018..
I see Valeant's NEW psoriasis drug siliq could do $800 million to $1 billion in 2018
They already predicting Novartis Cosentyx to hit $5.7 billion in sales in 2024
Can you imagine Valeant's siliq doing $1 billion in 2018 ? and $2 billion in 2020 ??
I wonder what Cramer will say today ??
looks like the whole float may have turned over this week !!!
A break out is a beautiful thing !!!!!!!!!
Bought another 2000 this morning.
Used up all the egg money !! LOL
Hope •Bank of America Merrill Lynch , Jeffries and UBS falls in love with VRX at the Health Care Conferences .
Im sure they are already nibbling !!!!!!!
JMHO as always
Stock House posters are cavalier with posting , love to see that also. Time will tell , as it always does !!